Technology & Applications
DNA Enabled Therapeutics
Reliant on DNA as a critical starting material, these treatments represent the next generation of advanced therapeutics, and are beginning to show unprecedented therapeutic outcomes in many devastating diseases
Viral gene therapy
Use of modified viruses as gene delivery vehicles to correct diseases caused by faulty gene expression. DNA is the critical starting material for the production of viral vectors for gene therapy.
Administration of live modified cells to a patient with the potential to transform the treatment paradigm for multiple diseases including cancer. DNA is the critical starting material used to modify cells prior to administration.
mRNA transmits information encoded on DNA and has huge potential to transform the vaccine and gene therapy treatment landscapes. mRNA requires a DNA template in order to be manufactured.
Direct modification of the genome using engineered nucleases with a wide range of therapeutic and non-therapeutic applications. DNA is the donor material for gene editing applications.
Advantages of dbDNA™
dbDNA™ constructs are the optimal starting material for the production of the next generation of DNA enabled therapeutics. Key benefits of dbDNA™ include:
Unprecedented yield, unlimited scalability These therapies require large quantities of DNA for development and ultimate commercialization. Our technology can cost-effectively meet the scale of DNA required for all stages of the product life-cycle.
Amplifies complicated secondary structures and repetitive sequences Enables manufacture of DNA sequences that are currently difficult or impossible to manufacture as plasmids, including hairpins, AAV ITRs, mRNA polyA.
No antibiotic resistance genes or bacterial sequences Our acellular process eliminates non-target bacterial sequences such as antibiotic resistance genes that are perceived negatively by regulatory authorities.
Error rate of < 1/107 Our process has a sequence fidelity that easily meets regulatory requirements.